Olof Tydén
Fondateur chez Eureda KB
Profil
Olof Kristian Tydén is the founder of Eureda KB, which was founded in 2000.
He holds the title of Partner at Eureda KB.
Dr. Tydén's former jobs include Director at BioXell SpA, Medical Director at LEO Pharma A and Pfizer AB, Independent Director at Oncopeptides AB, Director at Aprea Therapeutics AB and Cantargia AB, Senior Regulatory Adviser at F.
Hoffmann-La Roche Ltd., and Principal at European Health Telematics Association.
Dr. Tydén received a doctorate degree from the University of Uppsala.
Postes actifs de Olof Tydén
| Sociétés | Poste | Début |
|---|---|---|
| Eureda KB | Fondateur | 01/01/2000 |
Anciens postes connus de Olof Tydén
| Sociétés | Poste | Fin |
|---|---|---|
| CANTARGIA AB | Directeur/Membre du Conseil | 15/01/2014 |
| European Health Telematics Association | Corporate Officer/Principal | - |
Sista versen 26366 AB
 Sista versen 26366 AB Pharmaceuticals: MajorHealth Technology Sista Versen 26366 AB discovers treatments for inflammatory disorders. Their treatment is based on properties of new classes of endogenous host defense peptides from proteins within the coagulation cascade, which display potent immune-modulating properties. The firm develops drugs that prevent sepsis development. The company was founded by Artur Schmidtchen and Nils Martin Malmsten on October 26, 2009 and is headquartered in Lund, Sweden. | Directeur/Membre du Conseil | - |
Aprea Therapeutics AB
 Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Directeur/Membre du Conseil | - |
F. Hoffmann-La Roche Ltd.
 F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Corporate Officer/Principal | - |
Formation de Olof Tydén
| University of Uppsala | Doctorate Degree |
Expériences
Fonctions occupées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| CANTARGIA AB | Health Technology |
| ONCOPEPTIDES AB | Health Technology |
| Entreprise privées | 8 |
|---|---|
BioXell SpA
 BioXell SpA BiotechnologyHealth Technology BioXell SpA provides medical services. The company researches and develops drugs to treat urological, inflammatory, and related disorders. The company was founded in 2002 and is headquartered in Segrate, Italy. | Health Technology |
LEO Pharma A/S
 LEO Pharma A/S Pharmaceuticals: MajorHealth Technology LEO Pharma A/S develops, manufactures and markets drugs within the area of dermatology and critical care medicine. It supplies medicines to patients suffering from skin infections and diseases such as psoriasis and eczema, thrombosis, kidney disease and cancer. The company was founded by August Kongsted and Anton Antons in 1908 and is headquartered in Ballerup, Denmark. | Health Technology |
| Eureda KB | |
| Pfizer AB | |
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Health Technology |
Aprea Therapeutics AB
Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Health Technology |
Sista versen 26366 AB
Sista versen 26366 AB Pharmaceuticals: MajorHealth Technology Sista Versen 26366 AB discovers treatments for inflammatory disorders. Their treatment is based on properties of new classes of endogenous host defense peptides from proteins within the coagulation cascade, which display potent immune-modulating properties. The firm develops drugs that prevent sepsis development. The company was founded by Artur Schmidtchen and Nils Martin Malmsten on October 26, 2009 and is headquartered in Lund, Sweden. | Health Technology |
| European Health Telematics Association |